Vasopressin Use in Septic Shock From Türkiye

NCT06953297 | Completed

• 1 other identifier: 2025-5
• Study Type: observational
• Target: 146
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to examine the early hemodynamic effects and clinical outcomes of vasopressin use in patients with septic shock. The study aims to compare adult ICU patients who received norepinephrine alone versus those who received vasopressin in addition to norepinephrine. The main question it aims to answer is: Does adding vasopressin to norepinephrine improve blood pressure, lactate levels, and survival in patients with septic shock? Researchers used retrospective medical records of patients treated between January and December 2024. Data such as blood pressure, heart rate, lactate levels, and mortality were collected and analyzed to assess treatment response and outcomes.

Conditions

Septic Shock; Vasodilatory Shock; Critical Illness Sepsis, Severe; Critical Illness; Intensive Care Medicine; Vasopressor Therapy

Keywords

Septic Shock; Vasopressin; Norepinephrine; Vasopressor Therapy; Hemodynamic Response; ICU; Critical Care; intensive care unit; Mortality; Lactate; Mean Arterial Pressure; Türkiye

Outcome Measures

Primary Outcomes (1)

• Change in Mean Arterial Pressure (MAP) Within 24 Hours After Vasopressin Initiation

  Mean arterial pressure (MAP) will be recorded at vasopressin initiation and at 0, 2 and 6 hours following the first dose. The primary outcome is the absolute change in MAP from baseline to 24 hours in patients receiving adjunctive vasopressin compared to those receiving norepinephrine alone.

  6 hours after vasopressor initiation

Secondary Outcomes (3)

• All-Cause Mortality

  Up to Day 28 after ICU admission

• Change in Serum Lactate Levels

  6 hours

• Change in Norepinephrine Dose After Vasopressin Initiation

  6 hours

Study Arms (2)

Norepinephrine Only

Participants with septic shock who received norepinephrine as the sole vasopressor agent during their ICU stay. No adjunctive vasopressin or other vasopressors were administered. This group served as the reference for comparison of hemodynamic and clinical outcomes.

Norepinephrine Plus Vasopressin

Participants with septic shock who received adjunctive vasopressin in addition to norepinephrine. Vasopressin was initiated during the course of vasodilatory shock based on clinical judgment. The study evaluated hemodynamic response and mortality in this group compared to norepinephrine monotherapy.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Critically ill adult patients with septic shock admitted to the intensive care unit of a tertiary academic hospital in Türkiye. All participants received norepinephrine as a first-line vasopressor, and a subset received adjunctive vasopressin.

You may qualify if:

• Adult patients (≥18 years old) admitted to the intensive care unit (ICU)
• Diagnosed with septic shock according to Sepsis-3 criteria
• Treated with norepinephrine as the initial vasopressor
• Received norepinephrine alone or norepinephrine with adjunctive vasopressin
• Admitted between January 1 and December 15, 2024

You may not qualify if:

• Patients younger than 18 years
• Patients who received epinephrine or dopamine prior to or along with vasopressin
• Patients with incomplete clinical or hemodynamic data
• Readmitted ICU patients during the same hospitalization
• Patients with do-not-resuscitate (DNR) orders at ICU admission

Sponsors & Collaborators

• Karadeniz Technical University: lead

Study Sites (1)

Karadeniz Technical University, Faculty of Medicine

Trabzon, 61080, Turkey (Türkiye)

Location

Related Publications (1)

• Kucuk AO, Hocek AB, Aydin D, Acar B, Pehlivanlar E, Pehlivanlar Kucuk M. Exploring vasopressin use in septic shock: a retrospective cohort study from Turkiye (VASCO-TURK). BMC Anesthesiol. 2025 Nov 22;25(1):623. doi: 10.1186/s12871-025-03519-8.

  PMID: 41275079 DERIVED

MeSH Terms

Conditions

Shock, Septic; Critical Illness; Diabetes Insipidus

Condition Hierarchy (Ancestors)

Sepsis; Infections; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Shock; Disease Attributes; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Pituitary Diseases; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Intensivist, Assistant Professor

Study Record Dates

• First Submitted: April 17, 2025
• First Posted: May 1, 2025
• Study Start: January 1, 2024
• Primary Completion: December 15, 2024
• Study Completion: January 15, 2025
• Last Updated: May 1, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)